A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies

Sam Joseph Lubner, Jacqueline Mullvain, Scott Perlman, Michael Pishvaian, Joanne Mortimer, Katherine Oliver, Jennifer Heideman, Lance Hall, Jamey Weichert, Glenn Liu

Research output: Contribution to journalArticlepeer-review

Abstract

This study explores the imaging and therapeutic properties of a novel radiopharmaceutical, 131I-CLR1404. Phase 1a data demonstrated safety and tumor localization by SPECT-CT. This 1b study assessed safety, imaging characteristics, and possible antineoplastic properties and provided further proof-of- concept of phospholipid ether analogues retention within tumors. A total of 10 patients received 131I-CLR1404 in an adaptive dose-escalation design. Imaging characteristics were consistent with prior studies, showing tumor uptake in primary tumors and metastases. At doses of 31.25 mCi/m2 and greater, DLTs were thrombocytopenia and neutropenia. Disease- specific studies are underway to identify cancers most likely to benefit from 131I-CLR1404 monotherapy.

Original languageEnglish (US)
Pages (from-to)483-489
Number of pages7
JournalCancer Investigation
Volume33
Issue number10
DOIs
StatePublished - Nov 26 2015
Externally publishedYes

Keywords

  • Drug discovery
  • Phase 1
  • Radiotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of <sup>131</sup>I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies'. Together they form a unique fingerprint.

Cite this